NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Medical Devices · CAD

Profound Medical Corp. (PRN.TO) Stock Analysis

Profound Medical Corp. (PRN.TO) is a Medical Devices stock listed on TSX and quoted in Canadian Dollar.

PRN.TO

CA$9.54

+CA$0.10 (+1.06%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PRN.TO with… →

PRN.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$9.45
Previous Close
CA$9.44
Day's Range
9.45–9.58
52-Week Range
5.23–12.40
Volume
5.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.50
Valuation
Market Cap
CA$348.59M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
18.26
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.38
Financials (FY)
Revenue (FY)
CA$16.10M+50.73%
Net Income (FY)
−CA$42.57M
Profit marginThe share of revenue left as profit after all costs and taxes.
−171.56%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
36.54M
1-Year Return
+58.21%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
13.47K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PRN.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−11.42%
2025−0.28%
2024−2.70%
2023−23.34%
2022+1.54%
2021−45.55%
2020+77.56%
2019+168.18%
2018 (partial year)−45.00%

As of September 4, 2026.

PRN.TO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025CA$16.10M−CA$42.57M−264.4%
2024CA$10.68M−CA$27.82M−260.4%
2023CA$7.20M−CA$28.32M−393.4%
2022CA$6.68M−CA$28.67M−429.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$16.10MCA$11.39M−CA$41.25M−CA$42.57M−264.4%
2024CA$10.68MCA$7.04M−CA$33.06M−CA$27.82M−260.4%
2023CA$7.20MCA$4.31M−CA$28.65M−CA$28.32M−393.4%
2022CA$6.68MCA$3.02M−CA$29.60M−CA$28.67M−429.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PRN.TO Valuation vs Medical Devices Median

Median of 151 stocks
MetricPRN.TOMedical Devices medianvs median
P/S ratio18.262.986.1x the median
Profit margin−171.56%−1.69%169.9 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Profound Medical Corp. (PRN.TO) is capitalised at CA$348.59M on the latest close. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 162.

PRN.TO last closed at CA$9.54 on September 4, 2026. That is +CA$0.10 (+1.06%) against the previous close. The 52-week range on file runs from CA$5.23 to CA$12.40. The latest close sits 82.41% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of CA$16.10M. Against the prior fiscal year total of CA$10.68M, that is a change of +50.73%. The same year closed with a net loss of CA$42.57M. Profit margin runs at −171.56%. That is 169.9 percentage points below the Medical Devices median of −1.69%. Trailing earnings per share are −1.38.

Across the 4 fiscal years on file, revenue moves from CA$6.68M in 2022 to CA$16.10M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 18.26 times revenue. On price-to-sales that is 6.1 times the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

Beta against the wider market is reported at 0.5. Daily returns over the trailing 8 years annualize to a volatility of 69.52%. The trailing one-year price return is +58.21%. Measured over 5 years, that is −13.27% a year compounded.

Growth & Income

The record shows no dividend for PRN.TO.

The strongest complete calendar year on file is 2019 at +168.18%; the weakest is 2021 at −45.55%. Of the 7 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −11.42% year to date.

Peer Comparison

Profound Medical Corp. (PRN.TO) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Profound Medical Corp. PRN.TO CA$348.59M —
Abbott Laboratories ABT CA$187.45B 35.1
Medtronic plc. MDT CA$120.46B 22.9
Stryker Corporation SYK CA$116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Profound Medical Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Profound Medical Corp.

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.

Visit website →